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Although the intraaortic balloon pump (IABP) has 
been useful in supporting patients with specific me- 
chanical complications of infarction that could be 
approached with corrective surgery,l it has not been 
found to be useful as routine therapy in conserva- 
tively treated acute myocardial infarction. The con- 
cepts of using the IABP to reduce myocardial oxygen 
demand2 or to support the failing left ventricle3 have 
been theoretically attractive. However, in uncompli- 
cated myocardial infarction in the absence of reper- 
fusion, the IABP has not been shown to reduce inf- 
arct size.4 Furthermore, although short-term survival 
of patients in cardiogenic shock without correctable 
mechanical complications has been enhanced, the 
long-term outcome has remained unchanged by use 
of the IABP before the advent of reperfusion 
therapy.5 
Coronary artery reperfusion with thrombolytic 
therapy,6, 7 percutaneous coronary angioplasty,8 or 
both have offered a new opportunity to enhance out- 
come with the IABP by several possible mechanisms. 
Although reperfusion reduces infarct size and even- 
tually improves left ventricular function,s the func- 
tion of ischemic myocardium does not immediately 
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improve with reperfusion.lO Therefore supporting 
myocardial function with the afterload-reducing 
properties of the IABP may be beneficial while 
awaiting functional recovery. Furthermore, coronary 
flow is often impaired in the early phase of 
reperfusion. I1 Increasing diastolic coronary pressure 
and flow may enhance the effects of chemical and 
mechanical means of reperfusion.12 Against these 
potential benefits must be weighed the risks, espe- 
cially bleeding at the site of femoral artery puncture13 
and thrombotic complications resulting from ob- 
struction of flow to the legs.14 
The goal of the current study was to review the ex- 
perience with the use of the IABP in a large group of 
patients treated with thrombolytic therapy. In this 
process we evaluated the risks of the IABP and de- 
veloped hypotheses concerning the possible benefits 
of this procedure in specific subsets of patients in the 
setting of acute myocardial infarction. 
METHODS 
Patient population. The study population included 
810 consecutive patients who participated in four 
clinical trials evaluating different therapeutic strat- 
egies after administration of thrombolytic therapy. 
Results of these clinical trials have been reported in 
detail in previous publications.r5m1s Common to all 
protocols was the administration of thrombolytic 
therapy within 6 hours of the onset of symptoms. All 
patients met the following criteria: ECG evidence of 
at least 0.1 mV of ST segment elevation in two or 
more contiguous leads, absence of previous Q wave 
infarction in the distribution of acute ischemic re- 
gion, and symptoms of ischemia lasting longer than 
30 minutes and unresponsive to sublingual nitroglyc- 
erin therapy. Criteria for exclusion included a history 
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of significant risk of bleeding, previous major surgery, 
uncontrolled hypertension, cardiogenic shock, pro- 
longed cardiopulmonary resuscitation, or potential 
pregnancy. 
All patients underwent acute cardiac catheteriza- 
tion with a goal of visualization of the infarct-related 
artery within 90 minutes of administration of throm- 
bolytic therapy. In the Thrombolysis and Angio- 
plasty in Myocardial Infarction (TAMI) I trial,15 pa- 
tients with patent coronary arteries and suitable 
anatomy for angioplasty were randomly assigned to 
undergo immediate angioplasty or were considered 
for deferred angioplasty at the time of hospital dis- 
charge. In the TAM1 11,16 TAM1 111,17 and 
urokinase18 trials only patients with occluded in- 
farct-related arteries underwent immediate angio- 
plasty. In all of the patients an effort was made to 
defer angioplasty until the time of hospital discharge. 
The first 178 patients in the TAM1 I trial received 
150 mg of intravenous tissue plasminogen activator 
(t-PA) over 6 to 8 hours with 60 mg over the first hour, 
20 mg in the second and third hours, and 10 mg/hr for 
the last 5 hours. The remaining 208 patients were 
treated with 1 mg/kg in the first hour with a maxi- 
mum dose of 90 mg followed by the remainder of the 
150 mg dose over a &hour infusion period. The 146 
patients in the TAM1 II study received escalating 
doses of t-PA and urokinase. The first 34 patients 
received 25 mg of t-PA and 0.5 to 1 million units of 
urokinase. In the remaining 112 patients, 1 mg/kg 
t-PA was given in combination with 0.5 to 2.0 million 
units of urokinase. In the TAM1 III study all 175 pa- 
tients were treated with 1.5 mglkg of t-PA over 3 
hours. In the urokinase study 102 patients were 
treated with 3 million units of urokinase given over 
45 to 60 minutes. 
After acute angiography all patients were admitted 
to cardiac care unit where medical therapy was used, 
including intravenous lidocaine for 24 hours, and as- 
pirin and dilatiazem were given throughout the hos- 
pitalization unless adverse events or contraindica- 
tions were present. Heparin was given intravenously 
for up to 7 days with an effort to maintain the acti- 
vated partial thromboplastin time at 1.5 to 2 times 
greater than control values. Beta-blocking agents 
were withheld unless indicated for treatment of ven- 
tricular tachycardia, hypertension, or recurrent 
ischemia. Coronary artery bypass grafting was used 
only for very high-risk anatomy or other compelling 
clinical indications before follow-up angiography. 
After follow-up angiography, patients who were not 
considered to be candidates for angioplasty but who 
merited myocardial revascularization were treated 
with coronary artery bypass grafting. 
Core angiographic analysis. All coronary angiograms 
and left ventriculograms were analyzed at the Core 
Angiographic Laboratory at the University of Mich- 
igan. Observers were blinded to the specific treat- 
ment regimen. Global left ventricular ejection frac- 
tion was calculated by the area-length method,lg and 
regional left ventricular function was evluated by the 
centerline chord method of Sheehan et a1.2” 
Criteria for use of IABP. No standard criteria for in- 
sertion of the IABP were used in any of the four pro- 
tocols. The individual investigator at each center 
made the decision to insert the IABP based on the 
presence of demonstrated hemodynamic instability 
or coronary anatomy deemed to be extremely high 
risk. The reduction in reocclusion rates was not 
known until this study had been completed. There- 
fore this concept did not influence the selection of 
patients for IABP insertion. 
Method of IABP insertion. All IABP placements were 
carried out by a cardiologist experienced with the 
percutaneous insertion technique. The IABP was in- 
serted via the percutaneous route by means of the 
Seldinger technique. An 11F arterial sheath was used 
for placement in the femoral artery, and the IABP 
catheter was introduced by means of a guide wire. Ap- 
propriate position in the descending aorta was ver- 
ified by fluoroscopy in all instances. Adjustment in 
intravascular augmentation was verified by continu- 
ous measurement of arterial blood pressure. All pa- 
tients were anticoagulated with intravenous heparin 
while the IABP was being used. Removal of the IABP 
was performed with back bleeding from the arterial 
site for 5 to 10 seconds to allow intravascular thrombi 
around the insertion site to disappear. The inguinal 
region was then compressed manually for a minimum 
of 30 minutes. After removal of the IABP, any loss of 
pulse in the peripheral arteries distal to the insertion 
site was evaluated by a vascular surgeon. 
Collection and analysis of data. Data were entered 
onto case report forms at the clinical sites and the 
angiographic core laboratory, and the biostatistical 
core unit at Duke University provided quality control 
of the data. For descriptive purposes, results are ex- 
pressed as percentages for discrete variables and 
mean ( + 1 standard deviation [SD]) for continuous 
variables. 
RESULTS 
Baseline characteristics. A descriptive summary of 
selected clinical and angiographic baseline charac- 
teristics is shown in Tables I and II. As expected, pa- 
tients in whom the IABP was inserted had substan- 
tially more hemodynamic compromise, more multi- 
vessel and left anterior descending coronary artery 
disease, and more frequent failure to reperfuse at 
immediate angiography compared with patients in 
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Table I. Baseline characteristics Table II. Angiographic findings 
Patients Patients 
with IABP without IABP 
Characteristics (N = 85) (N = 725) 
Age (~1) 58 -+ 10 56 -t 9 
Male sex (‘,) 81 80 
Risk factors 
Diabetes ( “U ) 20 14 
Hypertension (‘I:;, ) 47 41 
Weight (pounds) 180 + 34 181 * 33 
Peripheral vascular disease (I’U) 9 5 
Cerebral vascular disease ($1) 2 2 
Previous myocardial infarction (5G) 25 12 
Location of myocardial infarction 
Anterior ( ‘0 ) 62 38 
Inferior ( ’ I# ) 38 62 
Admission systolic 127 k 25 133 * 25 
blood pressure (mm Hg) 
Admission heart rate 85 k 21 78 k 18 
Killip class > 1 ( “i, ) 30 19 
Patients Patients 
with IABP without IABP 
















whom the IABP was not inserted. The greater prev- 
alence of diabetes, hypertension, and older age also 
demonstrates the higher risk nature of the IABP 
population. 
Timing and circumstances of insertion. The majority 
of IABP insertions occurred in the first 24 hours of 
the hospital course. Over 90 % of insertions had been 
performed by the third day. The majority of the 
IABPs (75 % 1 were inserted before or during acute 
cardiac catheterization. Only four patients required 
insertion of the IABP later in the hospital course 
during or after cardiac surgery, whereas 16 IABPs 
(19%) were inserted during the stay in the cardiac 
care unit in patients treated without surgery. 
During the course of the four studies, the rate of 
IABP insertion ranged from a minimum of 10% in 
the TAM1 I trial to a maximum of 13 % in the TAM1 
II trial. Thus the rate of IABP insertion did not vary 
substantially over time. Similarly little variation ex- 
isted from center to center in IABP use, with rates 
ranging from 7% to 13% of patients. 
Clinical outcome. The in-hospital mortality rate of 
patients treated with IABP was substantially higher 
(32 % ) than that in patients not requiring IABP sup- 
port (4%). The majority of deaths were due to pro- 
gression of cardiogenic shock. No deaths resulted di- 
rectly from complications of IABP insertion. 
Table III shows multiple in-hospital clinical out- 
comes. As expected, because of the increased sever- 
ity of illness, patients treated with the IABP had a 
higher rate of arrhythmic and hemodynamic compli- 
cations compared with other patients. The length of 
hospitalization also was markedly longer in patients 










TIMI, Thrombolysis In Myocardial Infarction. 
The most intriguing outcome was the absence of 
reocclusion for the duration of IABP insertion com- 
pared with the overall rate of 13% in the combined 
trials. Careful scrutiny of individual records showed 
that there were two patients who had reocclusion 
within hours after removal of the IABP. In another 
three patients the IABP was inserted after reocclu- 
sion had occurred, because of hemodynamic compro- 
mise, and a second reocclusion did not occur. Review 
of records of the patients who died showed no rein- 
farction during treatment with the IABP, which was 
supported by the findings of patent infarct-related 
arteries at autopsy in 12 patients. Five patients who 
later died had a reinfarction before insertion of the 
IABP. 
The paired left ventricular function data are shown 
in Table IV. It is important that the number of paired 
observations is low in the group treated with IABP 
because of the high mortality rate, the severity of ill- 
ness, and the frequent use of surgery in these 
patients. Nevertheless, IABP patients with paired 
data had a tendency toward an improvement in rest- 
ing left ventricular function during the course of the 
hospitalization. These effects were most pronounced 
in the zone of myocardium distant from the site of 
infarction. 
Complications. Bleeding complications in patients 
with IABPs were substantially greater than in those 
without IABPs (Table V). Even when patients treated 
with coronary artery bypass grafting were excluded, 
significant differences remained. Vascular complica- 
tions were more common after IABP insertion com- 
pared with patients who only had the usual vascular 
access during their cardiac catheterization; loss of 
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with IABP without IABP 
(N = 85) (N = 725) 
Death 27 (32T ) 28 (4%) 
Reocclusion (total) 5 (7r<,)* 88 (13%) 
Reocclusion with IABP 0 - 
Pulmonary edema 32 (38%) 74 (10%) 
Sustained hypotension 48 (56%) 85 (12%) 
Ventricular tachycardia 35 (41$) 129 (185) 
or fibrillation 
Cardiac arrest 36 (42% ) 93 (13%) 
Hospital stay 27 + 34 days 12 -t 21 days 
*Three patients had reocclusion before the IABP was inserted; two patients 
had reocclusion after the IABP was removed. 





Global LV ejection fraction (“0 1 
Acute 40 i 13 52 + 11 
Follow-up 42 + 14 53 k 11 
Change +1.9 2 9.1 +0.7 +- 9.2 
Regional infarct zone function* 
Acute -3.17 + 0.76 -2.50 f 1.10 
Follow-up -2.63 i 1.04 -2.12 zt 1.25 
Change +0.38 ? 0.91 +0.38 f  1.05 
Regional noninfarct zone function* 
Acute -0.67 k 2.06 +0.36 ? 1.59 
Follow-up -0.71 r+ 1.84 +0.34 k 1.41 
Change +0.11 * 1.05 -0.09 + 1.20 
*Values expressed as standard deviations per chord. 
pulse occurred in 12 % versus 2 % and vascular repair 
in 6 % versus 2 % , respectively. Of the 27 patients 
with IABPs who later died, autopsy information was 
available in 42 % . There was only one patient who had 
a vascular dissection noted at autopsy in this group. 
The patient died of progressive cardiac failure, and 
the death could not be attributed to complications of 
IABP insertion. 
DISCUSSION 
The findings in this observational study indicate 
that the IABP may be inserted safely in the setting 
of acute myocardial infarction treated with throm- 
bolytic therapy, although the 11F vascular access re- 
quired in the femoral artery clearly increases the risk 
of bleeding and vascular trauma at the periaccess 
site. The most striking finding in this study was the 
absence of reinfarction or reocclusion of the infarct- 
related artery in a large consecutive series of patients. 
In addition, patients who had IABP insertion showed 
improvement in global and noninfarct zone regional 
left ventricular function. 
The greater severity of illness in the IABP group in 
every respect is not surprising, given the accepted 
indications for IABP use. In the absence of a control 
group we cannot accurately assess whether the ob- 
served 32% in-hospital mortality rate is lower or 
higher than would have been expected without 
IABP use. Similarly the potential impact on com- 
plication rates cannot be determined with confi- 
dence. Randomized trials will be necessary to de- 
termine the overall impact of the device on clinical 
outcomes. 
The apparent impact of the IABP on reocclusion 
cannot be accounted for by other factors that were 
measured in our population. In previous studies of 
reocclusion, the only factor we could find to be asso- 
ciated with a lower risk of reocclusion was a higher 
peak fibrin(ogen) degradation product level.“, 22 
Others”“, 24 have suggested that a lesser residual 
stenosis after thrombolysis was associated with a 
lower risk of reocclusion, but in this study the IABP 
group had a similar degree of residual stenosis com- 
pared with the non-IABP group. The possibility 
must be considered that a substantial number of 
reocclusion events occurred in the 27 patients who 
died. Careful review of their records, including au- 
topsy reports in 42% of patients, showed no evidence 
of reinfarction.25 
These findings are particularly pertinent to pa- 
tients undergoing “rescue angioplasty” because of 
failure of thrombolytic therapy to achieve reperfu- 
sion. In our previous experience the reocclusion rate 
in this “rescue angioplasty” group has been high26 
with an associated high mortality rate.26-2s The spec- 
ulated mechanism by which the IABP could prevent 
reocclusion is the production of markedly enhanced 
diastolic cornary artery perfusion pressure. The re- 
sultant improvement in flow characteristics could 
retard recurrent thrombus formation and prevent 
closure of an intimal flap after acute angioplasty 
against the opposite vessel wall. 
The serial left ventricular function data suggest 
that use of the IABP may enhance noninfarct zone 
function. These findings must be tempered, however, 
by consideration of the high death rate in the IABP 
group. Thus only “responders” may have survived, 
thereby providing an inaccurate impression of the 
overall effect of the intervention. Furthermore, pre- 
vious studies have demonstrated that patients with 
the poorest baseline left ventricular function have 
the greatest improvement regardless of other 
therapy. 2gs 3o Despite these reservations, serious con- 
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Table V. Complications of IABP 
Patients with IABP 
Overall (N = 85) Nonsurgical (N = 40) 
Patients without IABP 




Units transfused + Delta 
hematocrit f 3 
> 2 units transfused 
Local 
Femoral artery repair 
Loss of pulse 
27 k 5 29 * 5 32 i 6 33 z!z 5 
17 2 7 16 k 7 12 + 5 10 rf- 5 
12 + 8 8?7 5k4 4+3 
59 % 24% 17 “0 7”, 
6 % 5% 2T 2 (‘I 
12% 206 2 5 2 “0 
sideration should be given to the potential impact of 
improved coronary perfusion rates and afterload re- 
duction on recovery of myocardial function. 
Noninfarct zone function has recently been recog- 
nized as a critical factor in the assessment of 
prognosis.s1-33 In experimental studies when an epi- 
cardial vessel is occluded, collateral flow to other 
areas of myocardium with critical stenoses may be 
impaired.34 In the TAM1 experience absence of 
“compensatory hyperkinesis” in the noninfarct zone 
is a powerful predictor of in-hospital mortality.31 The 
IABP could reverse this phenomenon by three mech- 
anisms: (1) reduced afterload, thereby reducing the 
myocardial oxygen demand; (2) directly by improv- 
ing flow to the noninfarct zone across critical steno- 
sis; and (3) indirectly by improving collateral flow 
through the subendocardium. 
of data was rigorous and prospective, a specific pro- 
tocol for criteria for use of the IABP was not in effect. 
Thus the circumstances of insertion were not uni- 
form. Second, therapeutic effects cannot be directly 
assessed, since no adequate control group exists for 
comparison. Apparent effects of IABP use must be 
confirmed by other studies before these outcomes are 
extrapolated to other populations. Third, the results 
achieved in this study occurred in selected regional 
centers for the invasive care of patients with coronary 
disease. In the absence of the experience accumu- 
lated by these investigators, the complication and 
failure rates can be expected to be higher. 
The bleeding complication rates as expected were 
significantly higher with the IABP than without it. 
Much of this difference was attributable to the 
greater need for cardiac surgery in patients with 
IABPs, but the higher complication rate persisted 
after these patients were eliminated from the analy- 
sis. It is important that none of the complications di- 
rectly attributable to the IABP were considered to be 
life threatening. These complications are certainly 
directly related to the large size of the puncture hole 
produced by insertion of the IABP. 
The vascular complication rate of 12% observed 
in this study compares favorably with previously 
described complication rates of approximately 
20% .35-37 The relatively low incidence of vascular 
complications may be the result of the percutaneous 
insertion technique. 38 Although some vascular com- 
plications of the IABP may only be discovered at 
autopsy,3g just one patient had an adverse event 
noted at autopsy in this study. 
Before collection of these data, the rationale for 
using the IABP in conjunction with thrombolytic 
therapy predominately rested on the prolonged delay 
in recovery of myocardial function after reperfusion. 
Thus the IABP was used in these trials to provide 
hemodynamic support for patients with frank or im- 
pending cardiogenic shock. This study raises three 
additional issues for consideration in future trials 
and clinical practice. First, the absence of reocclusion 
in this population demands follow-up confirmation 
by independent studies. Second, improved global 
and noninfarct zone regional function in patients 
treated with the IABP may have resulted from 
enhanced flow in the presence of reperfusion or sig- 
nificant reduction in afterload.41, 41 Finally, the com- 
bined demonstration that noninfarct zone regional 
function is a critical determinant of survival and that 
it may be enhanced by use of the IABP raises the 
possibility that strategies could be developed to de- 
tect noninfarct zone dysfunction early, with the use 
of the IABP, to prevent subsequent hemodynamic 
deterioration. 
SUMMARY 
The limitations of this study must be recognized as To assess the risk and possible benefits of use of the 
the results are considered. First, although collection percutaneous IABP in patients given thrombolytic 
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therapy as treatment for acute myocardial infarction, 
we prospectively evaluated 810 consecutive patients 
entered into the TAM1 trials. During hospitalization 
the 85 patients treated with the IABP had more car- 
diac risk factors, were slightly older (58 vs 56 years), 
and more often had anterior infarction (62% vs 
38% ). At acute cardiac catheterization, patients 
treated with the IABP also had more multivessel 
coronary disease (67 % vs 43 % ), more frequent TIM1 
grade 0 or 1 flow (44 % vs 28 % ), lower global ejection 
fraction (40% vs 52%), and worse regional infarct 
(-3.2 vs -2.5 SD/chord) and noninfarct (-0.67 vs 
+0.36 SD/chord) zone function. Although mortality 
rates (32% vs 4%) and in-hospital complications 
were greater in patients treated with the IABP, a 
greater improvement in global (delta ejection 
fraction: +1.9% vs +0.7%) and noninfarct zone (del- 
ta SD/chord: +O.ll vs -0.09) left ventricular function 
was observed in patients treated with the IABP at 
l-week follow-up angiography. In addition, no rein- 
farction or reocclusion of the infarct-related artery 
occurred while patients were being treated with the 
IABP. 
These results suggest that the IABP may have a 
specific role after thrombolytic therapy in treating 
patients at high risk for reocclusion or at high risk for 
hemodynamic deterioration because of large infarc- 
tion or critical stenoses in coronary vessels supplying 
the noninfarct zone. 
The authors wish to acknowledge the assistance of Cynthia Day 
and Wendy Pulliam in the preparation of this manuscript. 
REFERENCES 
1. Levine FH, Gold HK, Leinbach RC, Daggett WM, Austen 
WG, Buckley MJ. Management of acute myocardial &hernia 
with intraaortic balloon pumping and coronary bypass sur- 
gery. Circulation 1978;58(suppl 1):1-69-I-72. 
2. Williams DO, Korr KS, Gewirtz H, Most AS. The effect of in- 
traaortic balloon counterpulsation on regional myocardial 
blood flow and oxygen consumption in the presence of 







Kantrowitz A. Krakauer JS. Rosenbaum A. Butner AN, Freed 
PS, Jaron D. Phase-shift balloon pumping in medically 
refractory cardiogenic shock. Arch Surg 1969;99:739-43. 
Flaherty JT, Becker LC, Weiss JL, Brinker JA, Bulkley BH, 
Gerstenblith G, Kallman CH, Weisfeldt ML. Results of a ran- 
domized prospective trial of intraaortic balloon counterpulsa- 
tion and intravenous nitroglycerin in patients with acute my- 
ocardial infarction. J Am Co11 Cardiol 1985;6:434-46. 
O’Rourke MF, Norris RM, Campbell TJ, Chang VP, Sammel 
NL. Randomized controlled trial of intra-aortic balloon coun- 
ternulsation in early myocardial infarction with acute heart 
failure. Am J Cardibl 1981;47:815-20. 
Braunwald E. Mvocardial renerfusion, limitation of infarct 
size, reduction of”left ventricular dysfunction, and improved 
survival. Circulation 1989,79:441-4. 
Califf RM, Top01 EJ, Gersh BJ. From myocardial salvage to 
patient salvage in acute myocardial infarction: the role of 


















American Heart Journal 
Top01 EJ. Coronary angioplasty for acute myocardial infarc- 
tion. Ann Intern Med 1988;109:970-80. 
Ton01 EJ, Califf RM. Tissue ulasminoaen activator: whv the 
backlash? J Am Co11 Cardiol‘1989;13:fi77-80. ” 
Braunwald E, Kloner RA. The stunned myocardium: pro- 
longed postischemicventricular dysfunction. Circulation 1982: 
66:1146-g. 
Grines CL, Top01 EJ, Bates ER, Juni JE, Walton JA, O’Neill 
WW. Infarct vessel status after intravenous tissue plasmino- 
gen activator and acute coronary angioplasty: prediction of 
clinical outcome. AM HEART J 1988;115:1-7. 
Fuchs RM, Brin KP, Brinker JA, Guzman PA, Heuser RR, Yin 
FCP. Augmentation of regional coronary blood flow by in- 
traaortic balloon counterpulsation in patients with unstable 
angina. Circulation 1983;68:117-23. 
Califf RM. TODO~ EJ. George BS. Boswick JM. Abbottsmith C, 
Sigmon KN, Candela R, Masekk, Kereiakes’D, O’Neill WW, 
Stack RS, Stump D, and the Thrombolysis and Angioplasty in 
Myocardial Infarction Study Group. Hemorrhagic complica- 
tions associated with the use of intravenous tissue plasmino- 
gen activator in treatment of acute myocardial infarction. Am 
J Med 198&85:353-g. 
Kantrowitz A, Wasfie T, Freed PS, Rubenfire M, Wajszczuk 
W, Schorkk MA. Intraaortic balloon pumping 1967 through 
1982: analysis of complication in 733 patients. Am J Cardiol 
1986;86:976-83. 
Top01 EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith 
CW, Candela RJ, Lee KL, Pitt B, Stack RS, O’Neill WW, and 
the Thrombolysis and Angioplasty in Myocardial Infarction 
Study Group. A randomized trial of immediate versus delayed 
elective angioplasty after intravenous tissue plasminogen ac- 
tivator in acute myocardial infarction. N Engl J Med 1987; 
317:581-6. 
Top01 EJ, Califf RM, George BS, Kereiakes DJ, Rothbaum D, 
Candela RJ, Abbottsmith CW, Pinkerton CA, Stump DC, 
Dollen D, Lee KL, Pitt B, Kline EM, Boswick JM, O’Neill 
WW, Stack RS, and the TAM1 Study Group. Coronary arte- 
rial thrombolysis with combined infusion of recombinant tis- 
sue-type plasminogen activator and urokinase in patients with 
acute myocardial infarction. Circulation 1988;77:1100-7. 
Top01 EJ. George BS, Kereiakes DJ, Stump DC, Cancela RJ, 
Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, 
Ellis SG. Califf RM. and the TAM1 Studv Grouu. A random- 
ized controlled trial of intravenous tissue plasminogen activa- 
tor and early intravenous heparin in acute myocardial infarc- 
tion. Circulation 1989;79:281-6. 
Wall TC, Phillips III HR, Stack RS, Mantel1 S, Aronson L, 
Boswick J, Sigmon K, DiMeo M, Chaplin D, Whitcomb D, Pasi 
D, Zawodniak M, Hajisheik M, Hegde S, Barker W, Tenney R, 
Califf RM. Results of high dose intravenous urokinase for 
acute myocardial infarction. Am J Cardiol 1990;65:124-31. 
Dodge HT, Sandler H, Ballew DW, Lord Jr JD. The use of bi- 
plane angiocardiography for the measurement of left ventric- 
ular volume in man. AM HEART J 1960;60:762-76. 
Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schafer J, 
Woo HW. Advantages and applications of the centerline 
method for characterizing regional ventricular function. Cir- 
culation 1986;74:293-305. 
Ellis SG, Top01 EJ, George BS, Kereiakes DJ, Debowey D, 
Sigmon KN, Pickel A, Lee KL, Califf RM. Recurrent ischemia 
without warning: analysis of risk factors for in-hospital is- 
chemic events following successful thrombolysis with intra- 
venous tissue plasminogen activator. Circulation 1989;80: 
1159-65. 
Stump DC, Califf RM, Top01 EJ, Sigmon K, Thornton D, 
Masek R, Anderson L, Collen D, and the TAM1 Study Group. 
Pharmacodynamics of thrombolysis with recombinant tissue- 
type plasminogen activator: correlation with characeristics of 
and clinical outcomes in patients with acute myocardial 
infarction. Circulation 1989;80:1222-30. 
Harrison DG, Ferguson DW, Collins SM, Skorton DJ, Erick- 
sen EE, Kioschos JM, Marcus ML, White CW. Rethrombosis 
Volume 121 









after reperfusion with streptokinase: importance of geometry 
of residual lesions. Circuilation 1984;69:991-9. 
White CW. Recurrent ischemic events after successful throm- 
bolysis in acute myocardial infarction: the Achilles’ heel of 
thrombolytic therapy. Circulation 1989;80:1482-5. 
Ohman EM, Sigmon K, Wall TC, Lee KL, Candela RJ, for the 
TAM1 Study Group. Why do people die after thrombolytic 
therapy? Circulation 1989;80:11-349. 
Califf RM, Top01 EJ, George BS, Boswick JM, Lee KL, Stump 
D, Dillon J, Abbottsmith C, Candela RJ, Kereiakes DJ, O’Neill 
WW, Stack RS, and the TAM1 Study Group. Characeristics 
and outcome of patients in whom reperfusion with intravenous 
tissue-type plasminogen activator fails: results of the throm- 
bolysis and angioplasty in myocardial infarction (TAM11 I 
trial. Circulation 1988;77:1090-9. 
Gacioch GM, Top01 EJ. Sudden, paradoxical clinical deterio- 
ration during angioplasty of the occluded right coronary 
arterv in acute mvocardial infarction. J Am Co11 Cardiol 1989; 
14:12-02-9. ” 
O’Connor CM, Mark DB, Hinohara T, Stack RS, Rendall D, 
Hlatkv MA. Prvor DB. Phillios III HR. Califf RM. Rescue 
coronary angioplasty after failure of intravenous streptoki- 
nase in acute myocardial infarction: in-hospital and long-term 
outcomes. J Invasive Cardiol 1989;1:85-95. 
Marzoll U, Kleiman N, Mulcahey S, Minor S, Verani M, 
Raizner A. Importance of baseline ejection fraction in response 
to reperfusion therapy in acute MI. Circulation 1988;78(suppl 
II):II-213. 
Califf RM, Parsons WJ, Tcheng JE, Hinohara T, Boswick JM, 
Honan MB, Wall TC. Baseline function, not time to treat- 
ment, is most closely associated with LV function improve- 
ment during the first week after thrombolvtic therapy. Circu- 
lation 1988>8(suppl II):II-213. 
_ 
Grines CL. Ton01 EJ. Califf RM. Stack RS. George BS. Kere- 
iakes D, B&wick JM, Kline E, ‘O’Neill WW, and the’TAM1 
Study Group. Prognostic implications and predictors of en- 
hanced regional wall motion of noninfarct zone after throm- 
bolysis and angioplasty therapy of acute myocardial infarc- 
tion. Circulation 1989;80:245-53. 










RH, Swain JL, Greenfield JC. Functional improvement of 
jeopardized myocardium following intracoronary streptoki- 
nase infusion in acute myocardial infarction. J Clin Invest 
1983;72:84-95. 
Schmidt WG, Sheehan FH, von Essen R, Uebis R, Effert S. 
Evolution of left ventricular function after intracoronary 
thrombolysis for acute myocardial infarction. Am J Cardiol 
1989;63:497-502. 
Wilson JL, Ramanathan KB, Ingram LA, Mirvis DM. Effects 
of residual stenosis on infarct size and regional transmural 
mvocardial blood flow after reperfusion. AM HEART J 
1988;116:1523-9. 
Iverson LIG. Herfindahl G. Ecker RR. Youne JN. Ennix CL. 
Lee J, Dunning C, Whisenant A, May IA. Va&&r complica: 
tions of intraaortic balloon counterpulsation. Am J Surg 
1987;154:99-103. 
Gottlieb SO, Brinker JA, Borkon M, Kallman CH, Potter SA, 
Gott VL, Baughman KL. Identification of patients at high 
risk for complications of intraaortic balloon counterpulsation: 
a multivariate risk factor analysis. Am J Cardiol 1984:53: 
1135-g. 
Goldberger M, Tabak SW, Shah PK. Clinical experience with 
intra-aortic balloon counterpulsation in 112 consecutive pa- 
tients. AM HEART J 1986;111:497-502. 
Vignola PA, Swaye PS, Gosselin AJ. Guidelines for effective 
and safe percutaneous intraaortic balloon pump insertion and 
removal. Am J Cardiol 1981;48:660-4. 
Isner JM, Cohen SR, Virmani R, Lawrinson W, Roberts WC. 
Complications of the intraaortic balloon counterpulsation de- 
vice: clinical and morphologic observations in 45 necropsy pa- 
tients. Am J Cardiol 1980;45:260-8. 
Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald 
E. Effect of captopril on progressive ventricular dilatation 
after anterior myocardial infarction. N Engl J Med 1988;319: 
80-6. 
Nabel EG, Top01 EJ, Galeana A, Bates ER, Werns SW, Wal- 
ton JA, Pitt B. A randomized, double-blind, placebo con- 
trolled, pilot trial of combined early intravenous captopril and 
tPA therapy in acute myocardial infarction. Circulation 
1989;8O(suppl II):II-112. 
